Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal polysaccharide vaccine, groups A, C, Y, and W-135 combined
- Development stage
- Discontinued
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**Meningococcal polysaccharide vaccine, groups A, C, Y, and W-135 combined** is an unconjugated quadrivalent capsular-polysaccharide vaccine formerly marketed in the United States as **Menomune A/C/Y/W-135** by Sanofi. It contains purified group-specific capsular polysaccharides from *Neisseria meningitidis* serogroups A, C, Y, and W-135 and induces serogroup-specific anti-capsular bactericidal antibody responses for active immunization against invasive meningococcal disease. Unlike MenACWY conjugate vaccines, it does not covalently link its polysaccharide antigens to a carrier protein. Menomune was administered as a reconstituted subcutaneous injection and is no longer commercially available in the United States.
- Brand names
- Menomune A/C/Y/W-135
- Other names
- MenACWY polysaccharide vaccineMPSV4MPSV-4MPSV 4quadrivalent meningococcal polysaccharide vaccine
02
Targets
Neuraminidase
Beyond the preview
Go deeper on meningococcal polysaccharide vaccine, groups A, C, Y, and W-135 combined.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal polysaccharide vaccine, groups A, C, Y, and W-135 combined.